Health Condition 1: null- Adult onset nephrotic syndrome.
Conditions
Interventions
Intervention1: Tacrolimus: Tacrolimus is an immunosuppressive macrolide of the calcineurin inhibitor group that is widely used following organ transplantation. Tacrolimus is already known to be effec
Sponsors
IPGMER and SSKM Hospital kolkata
Eligibility
Inclusion criteria
Inclusion criteria: All patients aged over 18 years with biopsy-proven MCD with an Immunofluorescence staining negative for all stains and presence of nephrotic range proteinuria ( >3.5gms/24hours) will be taken for study.
Exclusion criteria
Exclusion criteria: The patients with any other glomerular or tubulo-interstitial pathology in the biopsy (including any overlap syndrome or variants of MCD), chronicity features on histopathology (interstitial fibrosis and tubular atrophy >20%), presence of active infection and prior exposure to any immunosuppressive agents for the same disease were excluded from the study. Patients with systemic diseases like SLE, diagnosed lymphoma/leukemia or suspicion of drug induced MCD were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission, partial remission in each groups, tacrolimus and steroid resistance measured at 12 and 18 months in steroid and tacrolimus groups.Timepoint: 6 months 12 months, 18 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapses, sustained remission, complications of therapy, drug dependency measured at 18 months.Timepoint: 6 months, 12 months, 18 months | — |
Countries
India
Contacts
Public ContactDipankar Sircar
IPGMER and SSKM Hospital,kolkata
Outcome results
None listed